Resultados de la búsqueda 1-10 of 1512 for SC

  1. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and ...

  2. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

  3. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  4. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  5. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  6. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

  7. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  8. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  9. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  10. Oncología (médica) - Ensayos clínicos

    Also, to evaluate safety and tolerability and determine RP2D of YH001 in combination with envafolimab dosed at 600 mg SC every 3 weeks and doxorubicin dosed at ...